Atrium Therapeutics, Inc. Common Stock (RNA)
PHARMACEUTICAL PREPARATIONS
Atrium Therapeutics, Inc. Common Stock (RNA) is listed on Nasdaq, where it has traded since February 27, 2026.
- Listed On
- Nasdaq
- Listed Since
- February 27, 2026
- Employees
- 391
- Market Cap
- $142M
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 152 institutions reported holding RNA, with 14.3 million shares worth $192.8 million in aggregate. The largest reported holder was Sessa Capital IM,, with 1.5 million shares worth $20.2 million. Of the 5 largest holders listed below, 1 opened a new position in RNA, 2 added shares and 2 reduced their positions during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Sessa Capital IM, | 1,500,000 | $20M | Added 172.04% |
| T. Rowe Price | 1,472,984 | $20M | Reduced 5.17% |
| BlackRock | 1,447,476 | $19M | Added 20.09% |
| Vanguard | 947,572 | $13M | Reduced 11.6% |
| Crcm | 641,539 | $9M | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is RNA?
Atrium Therapeutics, Inc. Common Stock (RNA) is listed on Nasdaq, where it has traded since February 27, 2026.
Who are the largest institutional holders of RNA?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of RNA were Sessa Capital IM,, T. Rowe Price and BlackRock.
How many institutions own RNA?
152 institutions reported a position in RNA for the quarter ended June 30, 2026, worth $192.8 million in total.
Did institutions buy or sell RNA last quarter?
Of the 5 largest reported holders, 1 opened a new position in RNA, 2 added shares and 2 reduced their positions during the quarter. Every reported holder and its change is on the SentiSense ownership page for RNA.
Every reported institutional holder, plus insider and congressional trades in RNA, on SentiSense.